Researchers across major cancer centers have uncovered how metabolic byproducts, acidic tumor environments, and specialized enzymes drive therapy resistance in ovarian and blood cancers.
How Lactylation and Metabolism Fuel Cancer Persistence
A growing body of scientific insight is transforming how medical researchers understand cancer treatment resistance. At the center of this adaptability is metabolic reprogramming, where tumor cells shift their energy production to generate large amounts of lactate. Once thought to be merely a metabolic byproduct, lactate acts as a signaling molecule that fuels lactylation, a cellular process that modifies proteins and alters gene expression.
By bridging metabolism and gene regulation, lactylation enables cancer cells to rapidly adjust to hostile conditions. This process strengthens the ability of tumor cells to repair DNA damage, evade cell death, and maintain cancer stemness—a state associated with aggressive growth and recurrence. It also contributes to an immunosuppressive tumor microenvironment, which limits the effectiveness of immune-based treatments.
Additional studies in scientific literature highlight enzymes such as AARS1 acting as lactyltransferases that sense L-lactate and regulate protein modification, while class I histone deacetylases function as delactylases.
Targeting Tumor Acidity and p300 to Overcome PARP Inhibitor Resistance
In ovarian cancer, tumor acidity represents a major hurdle to long-term treatment success. Researchers at The University of Texas MD Anderson Cancer Center discovered that acidic environments activate a signaling network involving ERK, p300, and PARP1, which collectively regulate cellular signaling, gene activity, and DNA repair.
While PARP inhibitors effectively block a key DNA repair pathway—particularly in tumors carrying BRCA mutations—many cancers eventually develop resistance. Investigators found that ovarian cancer cells exposed to acidic conditions became significantly less sensitive to these drugs because the signaling pathway reduces PARP trapping, a process that locks PARP enzymes at sites of DNA damage.
“PARP inhibitors have transformed treatment for many patients with ovarian cancer, but resistance often limits their long-term effectiveness. This study revealed that the tumor microenvironment plays a critical role in driving treatment resistance and suggests a potential strategy for restoring sensitivity to PARP inhibitors and extending their benefit for patients.”
Rugang Zhang, professor and chair of Experimental Therapeutics at UT MD Anderson Cancer Center
Suppressing BTK Inhibitor Resistance by Blocking BRG1 and Ferroptosis
In blood cancers, investigators at Weill Cornell Medicine identified a distinct mechanism of resistance involving Bruton’s Tyrosine Kinase (BTK) inhibitors. These drugs reduce the activity of the enzyme BTK, choking off the ability of B cells to proliferate in malignancies such as mantle cell lymphoma. Unfortunately, these cancers often lose their sensitivity after a year or two of treatment.
A study published July 2 in Nature Communications revealed that resistant mantle cell lymphoma cells rely on aberrant activity of a protein called BRG1. While successful BTK inhibitor treatment kills sensitive cells by inducing ferroptosis—an iron-dependent form of cell death—aberrant BRG1 protects cells by suppressing ferroptosis.
Co-senior author Dr. Jihye Paik noted that these findings point to a potential new therapeutic vulnerability that could be targeted to overcome drug resistance and extend the benefit of BTK inhibitors for patients with B-cell cancers.
